Aspergillosis Treatment Global Market Report 2024

The global aspergillosis treatment market has grown strongly in recent years. It will grow from $2.97 billion in 2023 to $3.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to diagnostic advancements, demand for antifungal medications, increased incidence, invasive procedures.

The global aspergillosis treatment market is expected to see strong growth in the next few years. It will grow to $3.98 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to demand for transplant medicine, prevalence of hematologic malignancies, increasing investments in research and development, public health initiatives. Major trends in the forecast period include antifungal resistance, targeted therapies, therapeutic drug monitoring, drug development.

The escalating prevalence of fungal infections is anticipated to drive the expansion of the aspergillosis treatment market in the foreseeable future. Fungal infections, or mycosis, are conditions caused by fungi, affecting both humans and animals. Aspergillosis, a fungal infection, can impact various organs including the respiratory system, lungs, brain, kidneys, and others. Treatment for aspergillosis, like voriconazole, focuses on managing the fungal infection, alleviating symptoms, averting complications, and enhancing overall well-being. For instance, as reported by the Centers for Disease Control and Prevention (CDC) in July 2023, fungal hospitalization rates have seen an annual increase of approximately 8.5% per 10,000 hospitalizations, rising from 22.3 in 2019 to 26.8 in 2021. This surge in fungal infection prevalence is a key driver behind the growth of the aspergillosis treatment market.

The increasing healthcare expenditures are anticipated to be a significant factor propelling the expansion of the aspergillosis treatment market in the foreseeable future. Healthcare expenditures encompass all costs related to providing health services, family planning initiatives, nutrition programs, and emergency assistance with a primary focus on health. The escalation in healthcare spending is likely to lead to the development of more effective therapies and advanced medical technologies for the treatment of aspergillosis. For instance, in March 2023, as reported by the American Medical Association, healthcare spending in the US rose by 2.7% to reach $12,914 per person in 2021, totaling $4.3 trillion. Consequently, the surge in healthcare expenditures is a significant driver behind the growth of the aspergillosis treatment market.

The presence of side effects linked to treatment is projected to impede the growth of the aspergillosis treatment market. Aspergillosis, a serious ailment, manifests through a range of symptoms and complications. The primary approach to treating aspergillosis involves the use of antifungal medications, which can potentially lead to significant side effects, including damage to the kidneys and liver. For instance, as of January 2022, Voriconazole, a newer antifungal medication, stood out as the most effective treatment for invasive pulmonary aspergillosis, despite potential side effects such as visual disturbances, liver damage, and skin rashes. Another antifungal, Amphotericin B, is associated with side effects like kidney damage, fever, and chills. Consequently, the presence of treatment-related side effects acts as a constraint on the growth of the aspergillosis treatment market.

Prominent companies in the aspergillosis treatment sector are dedicated to introducing cutting-edge drugs and solutions to maintain their competitive edge. These breakthroughs in drug development broaden the spectrum of treatment options available for aspergillosis. An example of this progress is the introduction of posaconazole oral suspension, which offers more precise and efficient treatment choices for patients. Notably, in April 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Posaconazole oral suspension in the US for treating aspergillosis. This medication is particularly relevant for patients with severely compromised immune systems, like hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), who are at high risk of developing invasive aspergillus and candida infections. Furthermore, posaconazole oral suspension is recommended for oropharyngeal candidiasis (OPC), particularly when it proves refractory to itraconazole and fluconazole.

In April 2021, Pfizer Inc., a leading US-based biotechnology and pharmaceutical company, completed the acquisition of Amplyx Pharmaceuticals Inc. The strategic move, carried out for an undisclosed sum, is set to significantly bolster Pfizer's capabilities in infectious disease research and enhance its pipeline of anti-infective treatments. Amplyx Pharmaceuticals Inc., also based in the US, is renowned for its pioneering work in developing therapies for conditions like invasive aspergillosis and rare mold infections.

Major players in the aspergillosis treatment market are Basilea Pharmaceutica Ltd., Pfizer Inc., Johnson and Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, Astellas Pharma Inc., Regeneron Pharmaceuticals, Mylan N.V. , Sun Pharmaceutical Industries, Jazz Pharmaceuticals, Dr. Reddy's Laboratories, Cipla Ltd., Bruker Corporation, Hikma Pharmaceuticals PLC.

North America was the largest region in the aspergillosis treatment market in 2023. The regions covered in aspergillosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aspergillosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of aspergillosis treatment encompass allergic aspergillosis, chronic aspergillosis, invasive aspergillosis, and other variants. Allergic aspergillosis, also recognized as allergic bronchopulmonary aspergillosis (ABPA), denotes a specific allergic response to the Aspergillus fungus, most frequently associated with Aspergillus fumigatus. Various classes of drugs are utilized, including corticosteroids, antifungal medications, and others. These treatments can be administered through oral, injectable, and alternative routes, and are distributed through a range of channels such as hospital pharmacies, retail pharmacies, and others.

This report provides aspergillosis treatment market statistics, including aspergillosis treatment industry global market size, regional shares, competitors with an aspergillosis treatment market share, detailed aspergillosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the aspergillosis treatment industry. This aspergillosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aspergillosis treatment market consists of sales of immunotherapy drugs, echinocandin and azole antifungals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.